drugset
drugset / Trial / NCT04655118

Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

NCT04655118 ↗

Phase 2 Unknown 121 enrolled Telios Pharma, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis (Cohorts 1-3) or Indolent Systemic Mastocytosis (Cohort 5). Participants must be diagnosed with Myelofibrosis and be relapsed/refractory (e.g., having failed prior therapy), intolerant, or ineligible to receive JAKi treatment, or be diagnosed with Indolent Systemic Mastocytosis.

Timeline

Start
2020-10-22
Primary completion
2025-06-30
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject TL-895 Small molecule 150 mg Oral
Subject TL-895 Small molecule 300 mg Oral
Subject TL-895 Small molecule 450 mg Oral

Indications

indolent systemic mastocytosis myelofibrosis